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ABSTRACT 
BACKGROUND Neuroimaging studies show structural alterations in several brain regions in children and 
adults with attention-deficit/hyperactivity disorder (ADHD). Through the formation of the worldwide 
ENIGMA ADHD Working Group, we addressed weaknesses of prior imaging studies and meta-analyses 
in sample size and methodological heterogeneity.  
METHODS Our sample comprised 1713 participants with ADHD and 1529 controls from 23 sites (age 
range: 4-63 years; 66% males). Individual sites analyzed magnetic resonance imaging brain scans with 
harmonized protocols. Case-control differences in subcortical structures and intracranial volume (ICV) 
were assessed through mega- and meta-analysis.  
FINDINGS The volumes of the accumbens (Cohen’s d=-0·15), amygdala (d=-0·19), caudate (d=-0·11), 
hippocampus (d=-0·11), putamen (d=-0·14), and ICV (d=-0·10) were found to be smaller in cases relative 
to controls. Effect sizes were highest in children, case-control differences were not present in adults. 
Explorative lifespan modeling suggested a delay of maturation and a delay of degeneration. 
Psychostimulant medication use or presence of comorbid psychiatric disorders did not influence results, 
nor did symptom scores correlate with brain volume.  
INTERPRETATION Using the largest data set to date, we extend the brain maturation delay theory for 
ADHD to include subcortical structures and refute medication effects on brain volume suggested by 
earlier meta-analyses. We add new knowledge about bilateral amygdala, accumbens, and hippocampus 
reductions in ADHD, and provide unprecedented precision in effect size estimates. Lifespan analyses 
suggest that, in the absence of well-powered longitudinal studies, the ENIGMA cross-sectional sample 
across six decades of life provides a means to generate hypotheses about lifespan trajectories in brain 
phenotypes. 
FUNDING National Institutes of Health 
KEYWORDS: ADHD, Subcortical brain volumes, imaging, lifespan, meta-analysis, amygdala  
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Research in context 
Evidence before this study. After searching for all prior meta-analysis performed on brain volume 
differences in ADHD  including the subcortical regions until the 1
st
 of February 2015 using the search 
terms ‘ADHD’, ‘structural’, ‘brain’, and ‘meta-analysis [Title]’ and ‘english’ [Language] in Pubmed, we 
found four published meta-analyses. The largest of those meta-analysed data on 565 cases and 583 
controls (children only). The published meta-analyses had three major limitations: 1. Power was only 
sufficient to detect effect sizes of Cohen’s d of 0.15 and higher, which we know to be insufficient based on 
results in other psychiatric disorders. 2. Existing studies only used published data as source material, 
which limited their ability to address covariates that may vary among studies, like age, and medication. 3. 
The existing meta-analyses included studies using different segmentation software and quality control 
procedures, a limitation contributing to heterogeneity across samples. 
Added value of this study. The current multi-site study, with data on 1713 cases and 1529 controls 
included, is by far the largest and best-powered study to date on brain volumes in ADHD. Data of all sites 
were newly analyzed using harmonized methods. Our work implicates new structures, amygdala and 
hippocampus, in ADHD, and provides unprecedented precision in effect size estimates. Our results, 
covering most part of the lifespan, showed most pronounced effects in childhood.   
Implications of all the available evidence. We confirm, with high powered analysis, that ADHD patients 
truly have altered brains, i.e. that ADHD is a disorder of the brain. This is a clear message for clinicians to 
convey to parents and patients, which can help to reduce the stigma of ADHD and get a better 
understanding of ADHD. This way, it will become just as apparent as for major depressive disorder, for 
example, that we label ADHD as a brain disorder. Also, finding the most pronounced effects in childhood 
provides a relevant model of ADHD as a disorder of brain maturation delay.  
Finding the biggest effect in the amygdala is another important message, as it links ADHD to emotional 
regulation problems. Those are frequently found in patients with ADHD, but these disease characteristics 
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have not (yet) made it into the official DSM-criteria. Our work shows neurobiological support for the 
inclusion of this domain in the core ADHD phenotype. 
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INTRODUCTION 
Attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder with a prevalence 
of 5.3% in childhood
1
. Two-thirds of patients with an ADHD diagnosis in childhood continue to have 
persistent, impairing symptoms in adulthood
2
. ADHD is characterized by age-inappropriate symptoms of 
inattention and/or hyperactivity and impulsivity
3
. Many imaging studies, often in small samples, have 
reported brain structural and functional differences between individuals with ADHD and controls, both in 
childhood and adulthood. Five meta-analyses of structural neuroimaging studies in ADHD have been 
published (Table 1). The first meta-analysis pooled region of interest brain volumes studies
4
, while the 
others pooled voxel-based morphometry (VBM) studies
5-8
. Most consistent results across studies were for 
reduced volumes of (parts of) the basal ganglia for patients compared with healthy controls. Two meta-
analyses showed that, with increasing age, basal ganglia structural differences between cases and 
controls tended to decrease, and that stimulant treatment was associated with normalization of these 
brain structures
5,6
.  
Brain volumes have also been associated with clinical features of ADHD; smaller volumes of caudate, 
cerebellum, and frontal and temporal gray matter have been associated with greater symptom severity
9
. 
Also in the general population, ADHD symptoms correlated with volumetric brain measures
10,11
.   
Identifying structural brain differences in people with ADHD is important to further our insights into the 
nature of ADHD. So far, analyses of brain structures in ADHD have been limited in size and statistical 
power (Table 1); the sample size of the largest published meta-analysis on brain volume (n=565 cases 
and n=583 controls) allowed the identification of differences in brain volume with Cohen’s d effect sizes of 
≥0·15 with 80% power (G*Power
12
). Analyses of other psychiatric disorders show that smaller effects are 
likely
13
. Existing meta-analyses for ADHD only used published data as source material, which limited their 
ability to address covariates that may vary among studies, like age and medication
5,6
. In addition, the 
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existing meta-analyses included studies using variable methods and protocols such as the segmentation 
software and quality control. 
To overcome such issues and perform collaborative studies of maximal power, we founded the ENIGMA 
ADHD Working Group. This worldwide collaboration enabled analyses of existing individual data, 
improving upon earlier meta-analyses by basing analyses on the use of harmonized segmentation and 
quality control protocols. Our increased sample size compared to all earlier studies supported both mega- 
and meta-analysis (sMethods, appendix) designs across 60 years of the lifespan. We selected 
subcortical brain volumes as our target, because of neurodevelopmental theories hypothesizing ADHD to 
be linked to early-emerging, persistent subcortical abnormalities
14
 and building on the results of earlier 
meta-analyses, which showed that deviations in these volumes were most consistently observed. In 
addition, we investigated intracranial volume (ICV) as a measure of total brain volume. Analyzing data 
from 23 cohorts with a sample size of n=3200 enabled us to detect the case-control effect sizes observed 
in other psychiatric disorders. In addition, the mega-analysis design also allowed investigation of 
associations with symptom scores, age, psychostimulant medication use, and comorbidity with other 
psychiatric disorders.  
 
MATERIALS AND METHODS 
Contributing studies 
The ENIGMA ADHD Working Group was formed in 2013 to aggregate structural magnetic resonance 
imaging (MRI) data from participants with ADHD and healthy controls across the lifespan. Details about 
the diagnostic procedures for each site are listed in the appendix (sTable1). The group adopted a rolling 
inclusion design, in which new groups can join at any time, but data-freezes allow analysis at fixed time 
points. The data-freeze for the current subcortical analysis was set at February 8, 2015. The analyzed 
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sample comprised 23 cohorts, for details see Table 2. Each participating site had approval from its local 
ethics committee to perform the study and to share de-identified, anonymized individual data.  
 
Neuroimaging  
Structural T1-weighted brain MRI data were acquired and processed at the individual sites. The images 
were analyzed using standardized protocols to harmonize analysis and quality control processes 
(sMethods, appendix, and http://enigma.ini.usc.edu/protocols/imaging-protocols/). Fully-automated and 
validated neuroimaging segmentation algorithms based on FreeSurfer versions 5.1 or 5.3 were used 
(sTable1, appendix). To make sure no effects of FreeSurfer version influenced the results
13
, we 
performed an additional analysis, adding version number as a covariate to our main model (see below). 
For each participant, we computed ICV and left and right volumes of the accumbens, putamen, pallidum, 
caudate, thalamus, amygdala, and hippocampus. For further analysis, we used the mean of the left and 
right volume ((R+L)/2). For an overview of single site subcortical structures, see appendix (sFigure1). 
Outliers were determined at above and below 1.5-times the interquartile range per cohort and group 
(case/control) and were excluded (sFigure1, appendix)
15
.  
 
Case-control differences of subcortical brain volumes and ICV  
By pooling all available individual data from all cohorts, a mega-analysis (for explanation see the 
sMethods, appendix), we investigated the differences between cases and controls on subcortical 
volumes and ICV. After excluding collinearity of age, sex, and intracranial volume (ICV) (variance inflation 
factor <1.2) and normality testing, the mega-analysis of each subcortical volume was performed using a 
linear mixed model (lme) by running the package nlme in R (version3.1-117). The model included 
diagnosis (case=1 and control=0) as factor of interest, age, sex, and ICV as fixed factors, and site as 
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random factor. In the analysis of ICV, ICV was omitted as covariate from the model. Handedness was 
added to the model to correct for possible effects of lateralization, but was excluded from the model when 
there was no significant contribution of this factor. To calculate Cohen’s d effect size estimates, adjusted 
for age, sex, site, and ICV, we used the t-statistic from the factor diagnosis in the model. In a post-hoc 
analysis, left and right volumes were studied separately.  
To make sure that no unobserved factor biased our analysis of case-control differences, meta-analysis 
was also performed by linear regression analysis for each volume and for each sample separately, taking 
age, sex, and ICV into account. The R-package “metaphor” (version 1.9-1
16
) was used to perform an 
inverse variance-weighted, random-effects meta-analysis, in accordance with other ENIGMA Working 
Groups
13,15
 (sMethods, appendix). 
 
Effects of age 
The effect of age on subcortical volume and ICV was studied by running the above described model for 
groups stratified by age: in children aged 14 or younger, adolescents aged 15 until 21 years of age, and 
in adults, aged 22 and older. We removed samples that were left with 10 subjects or less due to the 
stratification. As it is likely that the effects of age do not strictly follow a linear model, we only report linear 
effects of age and the effect of age*diagnosis for the sake of being complete. In addition, more 
explorative modeling was done to better understand the effects of age, by plotting moving averages and 
using fractional polynomials to fit non-linear models to the data (sMethods, appendix).  
Significance threshold 
Multiple comparisons correction for 32 tests (8 volumes and 4 groups: all, children, adolescents, and 
adults) was applied by using a false discovery rate with q=0·05 resulting in a p-value significance 
threshold of p=0·156.  
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Exploration of effects of sex, psychostimulant medication, and clinical measures  
To explore the effects of sex on brain volume, the results of the term sex from the main model are 
reported. To examine associations between prior psychostimulant treatment and regional brain volume, 
the mega-analysis model was run again, including only patients with medication information available 
(sTable1, appendix). To test, whether acute effects of psychostimulant medication confounded possible 
brain volume differences between participants with ADHD and healthy controls, we excluded subjects 
treated with stimulants at the time of their participation in the study (participants receiving other types of 
treatment were retained). In addition, as previous meta-analyses had found an association between 
stimulants and brain volumes
5,6
, we compared patients, who had ever used stimulant medication, to 
patients, who were lifetime stimulant-naïve. We explored the effects of ADHD symptom scores and 
presence/absence of co-morbid disorders on those brain volumes that differed significantly between 
participants with ADHD and healthy controls, for details see appendix (sMethods and sTable2, 
appendix). 
Role of the funding sources 
The funders had no role in study design, data collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all of the data and the final responsibility to submit 
for publication. 
 
 
RESULTS 
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We included data from 1713 participants with ADHD and 1529 healthy controls (Table 2) with a median 
age of 14·0 (range 4-63) years.  
 
Case-control differences in subcortical volumes and ICV 
As shown in Table 3, the mega-analysis indicated that participants with ADHD had significantly smaller 
volumes for the accumbens, amygdala, caudate, hippocampus, putamen, and ICV. Post-hoc analyses for 
the subcortical regions showed these effects to be bilateral (sTable3, appendix). No effect of FreeSurfer 
version of handedness was found (sTable4&5, appendix). 
Results of the case-control meta-analysis were largely comparable to those of the mega-analysis, but 
volume differences for accumbens and hippocampus were not significant (sTable6, appendix). 
Heterogeneity (I
2
) across samples was low to moderate; heterogeneity was highest for hippocampus 
(sTable6, appendix) and might be indicative of non-linear effects of site for this structure. 
 
Effect of age 
Age-stratified analyses revealed significant case-control differences in children for the accumbens, 
amygdala, caudate, hippocampus, putamen, and ICV (Table 4 and Figure 1). Effect sizes were higher 
than those for the entire sample. In the adolescent group, there was a significant case-control difference 
in the hippocampus. In adults, none of the case-control comparisons remained significant. Figure 1 
suggested an interaction effect for age-group and diagnosis on hippocampus volume; this was nominally 
supported by linear interaction statistics (p=0.03; sTable7, appendix). Explorative modeling using moving 
averages (Figure 2) also showed the age effects to cluster early in life, with higher age of attaining peak 
volumes in the ADHD group. The moving averages also hinted at potential later onset of volume 
decrease in the ADHD group, most clearly seen in accumbens and putamen. Sample sizes after age 50 
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years were limited (sFigure3, appendix), and resulted in wider confidence intervals in the moving 
average analyses. The fractional polynomial analyses also supported different developmental models for 
ADHD cases and controls for amygdala, hippocampus, putamen, thalamus, and ICV (sFigure4 & 
sTable8, appendix). 
 
Effect of sex 
Consistent with literature documenting smaller brains in females
17
, all but two subcortical structures, 
accumbens and caudate, showed main effects of sex in the mega-analysis (Table 3). None of the 
volumes showed differential sex effects for participants with ADHD and controls. 
 
Effect of medication 
Information on current medication use was available for 1254 participants with ADHD; 455 participants 
with ADHD were on psychostimulant medication (methylphenidate or amphetamine) at the time of 
scanning, with over half of the studies using a washout period of 24/48 hours (sTable1, appendix); 799 
participants with ADHD were not taking stimulant medication at scan time. Case-control differences in 
brain volumes after excluding participants currently on stimulant medication (Table 5) were comparable in 
effect sizes to those observed in the main analysis.  
For 719 participants with ADHD, information was available on lifetime usage of stimulant medication. Of 
these, 82 participants (11%) had never taken stimulant medication, compared to 637 patients, who used 
stimulant medication somewhere in their lifetime for a period of more than 4 weeks. No differences in any 
of the volumes were found by directly comparing these two groups.  
  
Association of clinical measures with subcortical brain volumes and ICV 
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Meta-analysis of the correlation between ADHD symptom scores in cases and brain volumes revealed no 
significant effects; only a nominally significant effect (p=0.02) was observed for caudate volume (sTable9 
& sFigure6, appendix). Neither were there any significant correlations when only the childhood samples 
were entered in the meta-analysis. Also, the observed case-control brain volume differences were not 
explained by the presence of another comorbid psychiatric disorder (sTable10, appendix). 
 
DISCUSSION 
Here, we report the largest study to date of brain volume differences between participants with ADHD and 
healthy individuals. Through worldwide collaboration in the ENIGMA ADHD Working Group, data on 1713 
participants with ADHD and 1529 healthy controls were newly analyzed, using harmonized quality control 
and segmentation procedures. Compared to previous meta-analyses, our study newly identified 
amygdala, accumbens, and hippocampus volumes to be smaller in participants with ADHD, and extended 
earlier findings for reduced caudate and putamen volumes by showing those to be bilateral rather than 
unilateral
5,7
. Significant volume differences had small effect sizes (ranging from d=-0·10 to d=-0·19). 
Meta-analysis confirmed these results. Age-stratification showed volume differences to cluster in 
childhood, no differences were seen in adulthood. The volume differences were equally apparent in those 
treated with psychostimulant medication and those naïve to psychostimulants. Finally, no correlations 
with quantitative scores of ADHD symptoms were found in cases, nor did comorbidity with other 
psychiatric disorders explain the findings. 
The work presented here carries several important messages for the clinical field. First, our results 
coming from highly powered analysis, confirm that ADHD patients truly have altered brains, i.e. that 
ADHD is a disorder of the brain. This is a clear message for clinicians to convey to parents and patients, 
which can help to reduce the stigma that ADHD is just a label for difficult kids, and caused by incompetent 
parenting. We hope this work will contribute to a better understanding of ADHD in the general public, and 
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that it becomes just as apparent as for major depressive disorder, for example, that we label ADHD as a 
brain disorder. Second, finding the most pronounced effects in childhood and showing delayed peaks of 
subcortical volume maturation provides a relevant model of ADHD as a disorder of brain maturation 
delay. Third, the brain differences we have found are not caused by any co-morbid disorders, medication 
effects, or ADHD symptom severity, but are exclusively related to the ADHD diagnosis. Lastly, finding the 
largest effect in the amygdala is another important message, as it links ADHD to emotional regulation 
problems. Those are often present in patients with ADHD, but these disease characteristics have not (yet) 
been included into the official DSM-criteria. Our work shows neurobiological support for the inclusion of 
this domain in the core ADHD phenotype, asking for more acknowledgement of the importance of 
emotion regulation problems in the ADHD patient.  
 
Our findings for striatum volume reduction are in line with current models of ADHD
18
. Differences in 
caudate volume are the most consistent finding for ADHD
4-6
, and also smaller putamen volumes have 
been frequently reported
5-7
. Our study now provides robust effect size estimates for those structural 
differences and shows that effects are bilateral. Although identified before in a single study
19
, our findings 
extend the meta-analytic literature to the third striatal volume, nucleus accumbens. Novel meta-analytic 
findings of our study are for amygdala and hippocampus. Previous work in single studies had found 
effects in these structures
20-22
, but also failed to replicate in others e.g.
23,24
. For amygdala volume, which 
showed the largest effect size in our study (d=-0·19; d=-0·18 in children), and for accumbens, the lack of 
earlier meta-analytic evidence for its role in ADHD might be due to the fact that these are small structures, 
for which automatic segmentation performs less well
25
. A more highly powered analysis may therefore 
have been necessary to overcome the experimental inaccuracy of these measures. Prior work provides 
functional evidence for a role of amygdala, accumbens, and hippocampus in ADHD. Dysfunction of the 
amygdala is associated with difficulties recognizing emotional stimuli, callous unemotional traits, and with 
emotion regulation in general
26,27
. Difficulties in recognizing emotional stimuli, diminished emotional 
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reactions to pleasant stimuli, and higher levels of callous unemotional traits have all been linked to 
ADHD
28-31
, and amygdala volume has been associated with hyperactivity
20
. The accumbens, with its 
prominent role in reward processing, is central to motivational and emotional dysfunction in ADHD
18
. The 
results of the hippocampus are less straight-forward, as there is not so much evidence for a deficit in 
long-term memory in ADHD patients the hippocampus’ main function
32
. However, there are also reports 
on the hippocampus playing a role in the regulation of motivation and emotion, which is impaired in 
ADHD
33
.  
Importantly, effect sizes observed in our study were similar to those found for other psychiatric disorders 
analysed using the ENIGMA procedures, in particular major depression and bipolar disorder 
13,34
. The 
scale of the effects is consistent with expectations for a heterogeneous disorder like ADHD. The specific 
pattern of findings may partially differentiate ADHD from the other psychiatric disorders analysed using 
similar procedures, i.e. schizophrenia, bipolar disorder, and major depressive disorder
13,15,34
. Especially 
effects on caudate and putamen seem to be ADHD-specific among the four. However, as mostly adults 
were investigated for the other three disorders, formal analyses taking age into account will need to be 
performed to make valid statements.  
The results of the age-stratified analysis indicate that subcortical volume differences in ADHD are most 
prominent in children, and non-existent in adults. Our additional exploratory models suggest that this is 
not the entire story on age effects, though care in interpreting this result is needed because of the cross-
sectional design of this study. Based on our findings across different approaches, we propose a model of 
altered trajectories of subcortical volume in ADHD. Our data suggest a delayed peak volume in 
participants with ADHD, which is reminiscent of earlier reports of altered velocity of cortical development 
in a longitudinal sample
35
. This model should be confirmed by longitudinal analyses, especially since the 
childhood and adult ADHD samples included in this study represent different subgroups of the population: 
childhood ADHD samples include those who will later remit and those who will persist having ADHD in 
adulthood, the adult ADHD samples include only the latter. In addition to the delays in subcortical brain 
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maturation at early age, our exploratory work also tentatively suggest later onset of decreases in 
subcortical volumes beyond the 4
th
 decade of life in ADHD. However, since sample sizes in our analysis 
dropped dramatically above age 25 years, and we had insufficient data to study age effects after 60 
years, this work is still hampered by not having sufficient subjects per site to rule out site-biases in those 
age ranges. As long as ADHD in old age is still a blind spot in ADHD research, it will be difficult to test the 
validity of such findings.  
 
Prior meta-analyses found associations between the percentage of treated patients and right caudate and 
amygdala/uncus volumes
5,6
. In our analysis, in which we were able to directly compare treated to non-
treated participants with ADHD in a sample exceeding the size included in the two previous meta-
analyses 4-fold, we did not confirm such associations with brain volume. This is in line with the most 
recent meta-analysis
8
. However, since our study had a non-randomized, cross-sectional design, some 
caution to interpreting these results is warranted, as the design of this study was not optimal to test 
medication effects. Also, as both prior meta-analyses used voxel-wise maps, there is a possibility that the 
observed normalizing effects of medication were too local to be picked up by volumetry.  
 
We did not observe associations of brain volumes with clinical measures, i.e. comorbidity or ADHD 
symptom scores. The absence of an association with comorbidity suggests that the brain volume 
reductions are robustly linked to ADHD itself, rather than being a secondary phenomenon caused by 
comorbidity. The absence of significant associations between brain volumes and symptom ratings is not 
surprising, given that brain function is based on distributed networks of brain regions rather than 
individual brain regions
36
. Still, previous studies did find single volume-function associations
9,37
, which we 
do not replicate here. We also could not replicate an earlier reported (modest) correlation of a total brain 
volume measure highly related to ICV with ADHD symptom severity in a similarly sized population 
sample
10
. In addition to the above, not finding effects of symptom scores might also be due to the 
heterogeneity of the instruments used by different cohorts in our study and/or differences in raters 
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(clinicians, teachers, parents). In addition, the sample size was halved in this case-only analysis, and the 
distribution of scores was skewed to the clinical range. In line with models of fronto-striatal dysfunction in 
ADHD, one could hypothesize that cortical structures might play a more important role in the severity of 
symptoms in ADHD patients than the subcortical structures
14
.   
 
This study has several strengths and limitations. A clear strength is the sample size, being the largest 
mega-/meta-analysis to date, with enough power to detect effects as small as d=0.08. Another strength is 
the harmonization of segmentation protocols across all contribution sites, reducing imprecision caused by 
differences in methods. Nonetheless, diagnostic routines and acquisition of imaging data still differed 
between sites, a limitation contributing to heterogeneity across samples. A strength was also the 
opportunity for mega-analysis. While effect sizes were similar to the meta-analysis, the mega-analysis 
allowed a more powerful detection of case-control volume differences. Mega-analysis also enabled 
effects of age, sex, comorbidity, and medication to be studied, although accounting for site in these 
analyses might have somewhat masked age effects (as many studies had a restricted age range). 
Modeling age in a cross-sectional study is challenging but we have used several approaches to 
understand the effects of age, however, we should be cautious and interpret our findings as hypothesis-
generating for future studies.  
To conclude, this first result of our world-wide collaboration confirms and extends previous findings of 
reduced striatal volume in ADHD. Optimizing sample size and harmonizing methods across studies 
allowed us to identify additional differences in amygdala and hippocampal volumes potentially 
contributing to problems in emotion regulation, motivation, and memory in ADHD. Brain volume 
differences were most prominent in children. We invite interested researchers to join the next studies of 
the ENIGMA ADHD Working Group. In this way, we may optimally benefit from efforts already invested in 
individual studies to better understand this common yet still vexing disorder.   
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FIGURE LEGENDS 
FIGURE 1. Displayed are the Cohens d effect sizes of differences between patients with ADHD and 
healthy controlsfor subcortical volumes and ICV, for 4 separate groups:1.) all subjects, 2.) children only 
(<15years), 3.) adolescents only (15-21 years), and 4.) adults only (>21 years). *significant after false 
discovery rate (FDR) correction; †nominal significant at p<0.05 
FIGURE 2. Displayed are the moving averages, corrected for age, sex, ICV and site for the subcortical 
volumes. 
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TABLES and FIGURES 
Table 1. Overview of published structural neuroimaging meta-analyses in ADHD. 
Study Subjects Sample size 
(case/controls) 
Image 
analysis 
method 
Main results 
Valera et al., 
2007 
Children only 565/583 Brain 
volumetry 
Reduced volume of splenium of 
the corpus callosum, cerebral 
volume, and right caudate 
nucleus in patients. 
Ellison-Wright et 
al., 2008 
Children only 114/143 VBM Smaller right putamen / pallidum 
region in patients. 
Nakao et al., 
2011 
Children and 
adults 
378/344 VBM Smaller basal ganglia in patients. 
Increasing age and long-term 
medication use associated with 
reduced case-control differences. 
Frodl et al., 2012 Children and 
adults 
320/288 VBM Right globus pallidus, right 
putamen, and caudate are 
reduced in patients. Increasing 
age and treatment tended to be 
associated with reduced deficits 
in patients. 
Norman et al, 
2016 
Children and 
adults 
931/822 VBM Decreased grey matter volume in 
right basal ganglia, insula, 
ventromedial orbitofrontal cortex, 
medial prefrontal cortex, right 
anterior cingulate cortex. No 
association between the grey 
matter abnormalities and long-
term stimulant use 
VBM = voxel-based morphometry  
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Table 2. Overview of cohort characteristics. For a more detailed description and references for the 
assessments and neuroimaging procedures, see sTable 1 in the appendix.  
Sample name 
Site, country of 
origin 
N 
Total 
N Cases 
(M/F) 
N Controls 
(M/F) 
Age ± SD 
ADHD-WUE Würzburg, GER 118 32/30 26/30 39.68±11.44 
ADHD-DUB1 Dublin, IRL 75 27/9 31/8 22.29±5.23 
ADHD-DUB2 Dublin, IRL 20 16/4 - 33.65±10.15 
ADHD-Mattos Rio de Janeiro, BRA 17 10/7 - 22.94±1.39 
ADHD200-KKI Baltimore, USA 94 15/10 41/28 10.22±1.34 
ADHD200-NYU* New York, USA 260 115/36 54/55 11.47±2.92 
ADHD200-Peking Peking, CHN 245 90/12 84/59 11.70±1.96 
ADHD200-OHSU Oregon, USA 109 29/13 30/37 9.13±1.25 
ADHD-UKA Aachen, GER 181 95/7 53/26 11.21±2.68 
Bergen-adultADHD Bergen, NOR 81 21/17 16/27 31.21±6.74 
Bergen-SVG Bergen, NOR 54 20/5 20/9 10.05±1.20 
DAT-London London, GBR 56 27/0 29/0 15.78±2.10 
IMpACT-NL Nijmegen, NLD 245 49/76 49/71 35.49±11.39 
MGH-ADHD New York, USA 148 42/37 29/40 35.76±12.03 
NICHE Utrecht, NLD 158 68/10 67/13 10.42±1.95 
NYU ADHD New York, USA 80 22/18 22/18 31.58±9.44 
UAB-ADHD Barcelona, SPA 198 82/21 64/31 25.80±13.02 
ZI-CAPS Mannheim, GER 35 17/5 7/6 12.73±1.23 
ADHD-Rubia London, GBR 77 44/0 33/0 13.95±2.19 
NeuroImage-ADAM Amsterdam, NLD 182 73/24 57/28 17.16±3.19 
NeuroImage-NIJM Nijmegen, NLD 178 89/50 23/16 16.89±3.41 
NIH Bethesda, USA 502 168/83 168/83 9.97±3.09 
MTA Irvine, USA 129 73/15 31/10 24.6±1.4 
Total  3242 1713 1529 18.6±11.81 
*One subject was excluded because of missing gender status 
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Table 3. Results of the mega-analysis of subcortical brain volumes in the total sample. 
 
N Cases/ 
Controls 
Adjusted mean volume estimate (SEM)
1
 
Cases/Controls 
p-value  
for Diagnosis 
Cohen’s d (95%CI) 
Other significant terms 
in the model 
Accumbens 1652/ 1471 656·5 (1·2) /  673·7(2·1) 4·98x10
-9
 -0·15 (-0.22-   -0.08) ICV, Site, Age 
Amygdala 1598/1463 1554·1 (3·7) / 1577·8(3·7) 3·69x10
-7
 -0·19 (-0.26 - -0.11) Sex, ICV, Site 
Caudate 1659/1489 3927·8 (8·2) /  3964·6(8·6) 0·001 -0·11 (-0.18 - -0.03) ICV, Site, Age 
Hippocampus 1599/1436 4147·8 (8·1) / 4163·7(8·5) 0·004 -0·11 (-0.18 - -0.03) Sex, ICV, Site 
Pallidum 1651/1471 1764·8 (4·6) / 1763·7(4·9) 0·95 -0·00 (-0.07 - 0) Sex, ICV, Site, Age 
Putamen 1660/1497 6025·7 (13·7) / 6100·6(14·6) 6·36x10
-9
 -0·14 (-0.21 - -0.07) Sex, ICV, Site, Age 
Thalamus
#
 1405/1242 7683·3 (17·8) / 7611·6(18·5) 0·39 -0·03 (0·03 -  -0·10) Sex, ICV, Site, Age 
ICV 1693/1513 1513597·3 (2741·3) / 1501680·7(2924·7) 0·006 -0·10 (0·04 -  -0·16) Sex, Site, Age 
Bold p-values are significant at the FDR-corrected threshold of p=0·0156, italic p-values nominally significant at p<0·05 
#
thalamus volume was not available from 
the NIH sample.
1
Adjusted mean volume estimate and standard error of the mean, corrected for age, sex, ICV, and site. 
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Table 4. Results of the mega-analysis of subcortical brain volumes in the stratified age groups 
 Children (<15) Adolescents (15-21) Adults (21>) 
 
N Cases/ 
Controls 
p-value  
for 
Diagnosis 
Cohen’s d 
(95%CI) 
N Cases/ 
Controls† 
p-value  
for 
Diagnosis 
Cohen’s d 
(95%CI) 
N Cases/ 
Controls 
p-value  
for 
Diagnosis 
Cohen’s d 
(95%CI) 
Accumbens 810/827 0·0001 
-0·19 
(-0·29 - 0·10) 
323/224 0·61 
-0·04  
(-0·22 - 0·12) 
510/415 0·12 
-0·10 
(-0·23 - -0·03) 
Amygdala 767/820 0·0003 
-0·18 
(-0·28 - -0·08) 
321/226 0·12 
-0·14 
(-0·31 - 0·03) 
500/412 0·03 
-0·14 
(-0·27 - -0·01) 
Caudate 825/840 0·006 
-0·13 
(-0·23-  -0·04) 
324/224 0·28 
-0·10 
(-0·27 - 0·07) 
502/420 0·30 
-0·07 
(-0·20 - 0·05) 
Hippocampus 764/802 0·012 
-0·12 
(-0·22 - -0·03) 
320/225 0·006 
-0·24 
(-0·42 - -0·08) 
506/404 0·38 
0·06 
(-0·07 - 0·19) 
Pallidum 816/831 0·79 
-0·01 
(-0·11 - 0·08) 
321/223 0·78 
0·02 
(-0·15 - 0·20) 
506/412 0·51 
0·04 
(-0·08 - 0·17) 
Putamen 836/854 0·0002 
-0·18 
(-0·28 - -0·09) 
329/228 0·83 
-0·02 
(-0·19 - 0·15) 
499/416 0·23 
-0·08 
(-0·21- 0·05) 
Thalamus
#
 604/616 0·89 
0·01 
(0·06 - -0·10) 
288/202 0·74 
0·03  
(-0·15 - 0·21) 
503/416 0·28 
-0·07 
(-0·20 - -0·06) 
ICV 837/854 0·003 
-0·14 
(0·04 - -0·24) 
330/229 0·13 
-0·13 
(-0·30 - 0·04) 
515/422 0·91 
0·01 
(0·06 - -0·12) 
Bold p-values are significant at the FDR-corrected threshold of p=0·0156, italic p-values nominally significant at p<0·05 
#
thalamus volume was not available from 
the NIH sample. † Due to a sample size lower than 10, the data for the following cohorts in analysis of the adolescent group were omitted: ADHD-Mattos (n=2), 
ADHD-WUE (n=2), BergenAdultADHD (n=4), MTA (n=2), Niche (n=7), ZI-CAPS (n=2).  
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Table 5. Results of the exploration of the effect of medication on case-control differences 
 Patients currently not taking stimulants versus 
controls
*
 
Stimulant use in patients: positive versus negative lifetime 
history 
 n Cases/ 
Controls 
Cohen’s d (95%CI) p-value for 
Diagnosis 
n Never / ever stimulant 
use in patients only 
p-value for positive versus 
negative for lifetime stimulant 
use 
Accumbens 776/1484 -0·12 (-0·21 - -0·03) 0·007 79/625 0.32 
Amygdala 753/1474 -0·18 (-0·27 - -0·10) 4·90x10
-9 
80/590 0.41 
Caudate 777/1502 -0·10 (-0·19 - -0·01) 0·02 80/627 0.15 
Hippocampus 757/1446 -0·08 (-0·17 - 0·003) 0·06 80/593 0.69 
Pallidum 776/1484 0·01 (-0·07 - 0·10) 0·74 79/621 0.26 
Putamen 784/1508 -0·13 (-0·22 - -0·04) 0·004 81/627 0.29 
Thalamus 692/1253 -0·03 (0·04 - -0·12) 0·53 80/458 0.29 
ICV 793/1512 -0·06 (0·04 - -0·16) 0·15 81/632 0.92 
*
within this group, 152 subjects were lifetime positive for the use of stimulant medication, 82 were lifetime negative; for 565 no lifetime information was available.  
